Anivance AI Corporation
Anivance AI combines organ chips with Multi-Agent AI. With 35 patents and global collaborations, we deliver plug-and-play platforms and LaaS services, supporting rare disease and inhalation models, diverse preclinical studies, and predictive, clinically-relevant data for accelerated drug discovery.
CanChip GmbH
We are a commercial provider of a microphysiological system either as a product or service.
TheWell Bioscience
TheWell Bioscience provides xeno-free, 3D cell culture solutions, empowering research in organoids, regenerative medicine, and drug discovery.
VoxCell
VoxCell empowers scientists and drug developers to study drug behavior with unprecedented physiological relevance. With vascular complexity at the core of our innovation, VoxCell delivers human-like models that accelerate therapeutic discovery and bridge the gap between preclinical and clinical phases. Committed to innovation and excellence, VoxCell continues to expand its impact on a global scale.
Bioprinting Laboratories
Bioprinting Labs’ pillar/perfusion plates enable robust and reproducible organoid culture and in situ analysis. Our products streamline organoid-based assays by facilitating miniature organoid culture and enhancing organoid maturity through dynamic culture in the pillar/perfusion plates.
AIM Biotech
AIM Biotech is a leading bioengineering company, offering scalable, cost-effective 3D cell culture platforms, drug screening services, and customized assay development. By combining model realism and platform simplicity, AIM’s plug-and-play technologies empower drug developers to mimic human biology with precision, delivering clinically-relevant data.
Nilogen Oncosystems
Provision of untouched intact tumor tissue platform to allow for the investigation of clinical relevant biomarkers, mechanism of action, safety and efficacy of therapeutics.
Exir Bio
Exir Bio’s goal is to accelerate drug discovery, efficacy, and safety assessments by combining nonhuman primate (NHP) in vitro / in vivo models,
replacing, reducing, and refining (3R’s) the use of NHPs – necessary due to the global shortage of NHPs and in accordance with US Modernization Act
2.0.
Exir Bio has access to ~20,000 NHP’s / 8 species across several colonies in the US, all with known origin and bred in captivity per FDA and European
Union requirements.
STEMCELL Technologies
We are the world-leading provider of reagents and services for generating organoid and stem cell-derived models of healthy and diseased human tissues.